H. Pylori Diagnosis and Treatment
Diagnosis
For diagnosis, use noninvasive testing with urea breath test (UBT) or stool antigen test as first-line methods in most patients, reserving endoscopy with biopsy for those with alarm symptoms or when direct visualization is clinically indicated 1.
Diagnostic Method Selection
Noninvasive testing (preferred for most patients):
Serology (IgG antibodies): Generally NOT recommended 1
- Remains positive long after eradication (creates a "serologic scar")
- Only acceptable when very high pretest probability exists (e.g., active duodenal ulcer)
- If used, confirm active infection with UBT or stool antigen before treating
- IgA and IgM tests are not FDA-approved and should be avoided
Endoscopy with biopsy: Reserved for specific situations
Critical Testing Pitfalls
Stop PPIs for 2 weeks before testing - they reduce bacterial load and cause false negatives in UBT, stool antigen, rapid urease test, culture, and histology 1. Antibiotics and bismuth have the same effect. H2-receptor antagonists can be substituted during this period. However, a positive test despite these medications can be trusted - these factors don't cause false positives.
Treatment
For treatment-naive patients, use bismuth quadruple therapy (PPI + bismuth + metronidazole + tetracycline) for 14 days as first-line empiric therapy when antibiotic susceptibility is unknown 5, 6.
First-Line Treatment Regimens
The choice depends on local clarithromycin resistance rates and bismuth availability:
Bismuth Quadruple Therapy (PBMT) - PREFERRED 6, 5
- PPI (standard or high dose) twice daily
- Bismuth subsalicylate 524 mg four times daily (or equivalent)
- Metronidazole 500 mg three to four times daily (total 1.5-2 g/day)
- Tetracycline 500 mg four times daily
- Duration: 14 days 6
- Why preferred: Effective even with dual clarithromycin-metronidazole resistance; metronidazole resistance in vitro doesn't significantly affect outcomes when adequate dosing used 3
Concomitant Non-Bismuth Quadruple (PAMC) 6
- Use when bismuth unavailable in high clarithromycin resistance areas
- PPI twice daily + amoxicillin 1000 mg twice daily + metronidazole 500 mg twice daily + clarithromycin 500 mg twice daily
- Duration: 14 days
Rifabutin Triple Therapy (PAR) 5
- Suitable empiric alternative in penicillin-tolerant patients
- PPI twice daily + amoxicillin 1000 mg twice daily + rifabutin 150 mg twice daily
- Duration: 14 days
- Resistance to rifabutin is rare 4
PPI-Clarithromycin Triple Therapy (PAC or PMC) - RESTRICTED
- Abandon when local clarithromycin resistance >15-20% 3
- Only use in areas with documented low (<10%) clarithromycin resistance 3
- If used: PPI twice daily + amoxicillin 1000 mg (or metronidazole 500 mg) twice daily + clarithromycin 500 mg twice daily for 14 days
Key Treatment Principles
Use high-dose PPIs - Increases efficacy by 6-10% 3. Consider:
- Esomeprazole or rabeprazole 40 mg twice daily (more potent than omeprazole)
- PPIs not metabolized by CYP2C19 in refractory cases 4
- Potassium-competitive acid blockers if available 4, 5
Amoxicillin dosing: Minimum 2 g daily divided three to four times daily to avoid low trough levels 4
Treatment duration: 14 days superior to 7-10 days (improves success by ~5%) 3, 6. All first-line therapies should be 14 days 6.
Salvage Therapy (After First-Line Failure)
After Failed Bismuth Quadruple Therapy 4
Use levofloxacin triple therapy OR rifabutin triple therapy as second-line (shared decision-making):
- Levofloxacin triple (PAL): PPI twice daily + amoxicillin 1000 mg twice daily + levofloxacin 500 mg once daily for 14 days
- Rifabutin triple (PAR): As described above
- Alternative bismuth quadruple regimen with different antibiotics (e.g., PBLA: PPI + bismuth + levofloxacin + amoxicillin)
After Failed Clarithromycin Triple Therapy 3
Use bismuth quadruple therapy OR levofloxacin triple therapy:
- Rationale: Abandon clarithromycin due to likely resistance selection 3
- Both regimens have Level 1a evidence 3
Critical Salvage Principles
Review antibiotic history thoroughly 4:
- Prior macrolide exposure → avoid clarithromycin
- Prior fluoroquinolone exposure → avoid levofloxacin
- Amoxicillin, tetracycline, rifabutin resistance is rare - can reuse 4
After TWO failed therapies with confirmed adherence: Consider H. pylori susceptibility testing to guide subsequent regimens 4
Metronidazole dosing in salvage: Use adequate doses (1.5-2 g daily) with bismuth - improves success despite in vitro resistance 4
Penicillin allergy: Consider allergy testing to delist the allergy (unless anaphylaxis history) - enables amoxicillin use 4
Levofloxacin caution: Rising resistance rates globally 3. Don't use in patients with chronic lung disease who may have received fluoroquinolones 3
Post-Treatment Confirmation
Perform test-of-cure in ALL patients 4+ weeks after completing therapy 3, 5:
- Use UBT or stool antigen test (NOT serology) 3
- Wait minimum 4 weeks after treatment completion
- Ensure patient off PPIs for 2 weeks before testing
Common Pitfalls to Avoid
Inadequate adherence: Explain rationale, dosing, expected side effects, and importance of completing full course before prescribing 4
Insufficient acid suppression: Major cause of failure 4. Use high-dose, potent PPIs
Using clarithromycin empirically in high-resistance areas: Clarithromycin resistance is now >20% in most of Central, Western, and Southern Europe and many US regions 3
Short treatment duration: 7 days is inadequate; use 14 days 6
Not testing for eradication: Untreated H. pylori leads to peptic ulcers, MALT lymphoma, and gastric cancer 7, 8
Using serology for post-treatment testing: Remains positive after eradication 1
Testing patients on PPIs: Causes false negatives 1